Medical Condition News

RSS

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

3 Feb 2011

Merz introduces new educational website for patients with focal dystonias

In support of the focal dystonia community, Merz Pharmaceuticals today announced the launch of a new educational website, FocalDystoniaExchange.com, where people affected by certain focal dystonias, as well as caregivers, family and friends, can learn more about the conditions and access helpful resources. For people who suffer from focal dystonias, completing simple, everyday tasks can be a difficult and challenging process.

3 Feb 2011

Vegetarians, vegans need to increase omega-3 fatty acids and vitamin B12 to reduce heart disease risk

People who follow a vegan lifestyle - strict vegetarians who try to eat no meat or animal products of any kind - may increase their risk of developing blood clots and atherosclerosis or "hardening of the arteries," which are conditions that can lead to heart attacks and stroke. That's the conclusion of a review of dozens of articles published on the biochemistry of vegetarianism during the past 30 years.

3 Feb 2011

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.

3 Feb 2011

LSU biochemists develop 5-LOX 3-D model to design effective asthma medication

Chronic inflammation has been directly associated with heart disease and other physical ailments. But LSU graduate student Nathanial Gilbert and Professor of Biological Sciences Marcia Newcomer, together with Associate Professor Sue Bartlett, have developed the first 3-D model of Human 5-Lipoxygenase, or 5-LOX, the molecule responsible for creating inflammatory compounds that provoke asthma.

3 Feb 2011

Study finds contradictory role of RIP1 protein in the liver during sepsis

Researchers from Rhode Island Hospital have identified a protein that plays a dual role in the liver during sepsis. The protein, known as RIP1, acts both as a "death switch" and as a pro-survival mechanism. The ability to identify the triggers for these functions may play a key role in treating sepsis in the future. The study is published online in advance of print in the journal Shock.

3 Feb 2011

Malarial drugs may help treat specific form of frontotemporal dementia

Frontotemporal dementia is caused by a breakdown of nerve cells in the frontal and temporal region of the brain, which leads to, among other symptoms, a change in personality and behavior. The cause of some forms of frontotemporal dementia is a genetically determined reduction of a hormone-like growth factor, progranulin.

3 Feb 2011

Poor adolescents with strong community get protection from risky health behaviors

Children who grow up in poverty have health problems as adults. But a new study finds that poor adolescents who live in communities with more social cohesiveness and control get some measure of protection; they're less likely to smoke and be obese as adolescents.

3 Feb 2011

Older people with metabolic syndrome may face high risk of developing memory loss

Older people with larger waistlines, high blood pressure and other risk factors that make up metabolic syndrome may be at a higher risk for memory loss, according to a study published in the February 2, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

3 Feb 2011

Positive results from Factor IX-CTP comparative study in hemophilic mice

PROLOR Biotech, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX in Factor IX-depleted hemophilic mice.

3 Feb 2011

Scientists challenged to sequence genome and RNA content derived from single cancer cell

Life Technologies Corporation today announced that the Life Grand Challenges Contest, initially introduced in December 2010, is expanding to include a fourth challenge. This latest contest challenges scientists to sequence the genome and all RNA content derived from a single cancer cell using the 5500 Series SOLiD™ Sequencers.

3 Feb 2011

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

2 Feb 2011

USPTO issues notice of allowance to Vermillion's breast cancer biomarkers

Vermillion, a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent entitled "Biomarkers for breast cancer" to the Company.

2 Feb 2011

New study: Clinical trials exclude older patients due to age-related conditions

Older individuals, who constitute a rapidly growing population in the United States, account for a disproportionate share of health care utilization and cost. Yet more than half of clinical trials exclude people based on their age or age-related conditions, according to a new study by Robert Wood Johnson Foundation Clinical Scholars- at the University of Michigan.

2 Feb 2011

Researchers discover potential vaccine capable of reducing H. pylori colonization

A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of Helicobacter pylori -- a known cause of gastritis, ulcer disease and cancer.

2 Feb 2011

Study: Simple sideline test can accurately detect concussions in athletes

A simple test performed at the sideline of sporting events can accurately detect concussions in athletes, according to study by researchers at the University of Pennsylvania School of Medicine. Current sideline tests can leave a wide amount a brain function untested following concussion.

2 Feb 2011

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2011 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

2 Feb 2011

Cutera launches Excel V laser system for Dermatologists and Plastic Surgeons

Cutera, a leading worldwide provider of laser and other energy-based aesthetic systems for practitioners worldwide, today announced the launch of its Excel V laser system ─ a unique vascular work station designed specifically for the core-market of Dermatologists and Plastic Surgeons.

2 Feb 2011

2010 Dietary Guidelines urge Americans to keep calorie intake from saturated fat to less than 10%

This week the U.S. government released the 2010 Dietary Guidelines for Americans with few changes since the 2005 version. The guidelines continue to urge Americans to keep their calorie intake from saturated fat to less than 10 percent and lower the amount of trans fat in their diet to as low as possible.

2 Feb 2011

Study suggests human amniotic cells 'cross talk' with melatonin receptor MT1

Human amniotic epithelial cells, stem cells derived from human placenta left over from live births and generally discarded, proliferated and differentiated when they interacted with one kind of melatonin receptor, MT1. This potentially therapeutic response occurred when the stem cells were transplanted into laboratory test tube and animal models of stroke. The same cells did not perform similarly when interacting with melatonin receptor MT2.

2 Feb 2011

Medical Condition News

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Merz introduces new educational website for patients with focal dystonias

Vegetarians, vegans need to increase omega-3 fatty acids and vitamin B12 to reduce heart disease risk

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

LSU biochemists develop 5-LOX 3-D model to design effective asthma medication

Study finds contradictory role of RIP1 protein in the liver during sepsis

Malarial drugs may help treat specific form of frontotemporal dementia

Poor adolescents with strong community get protection from risky health behaviors

Older people with metabolic syndrome may face high risk of developing memory loss

Positive results from Factor IX-CTP comparative study in hemophilic mice

Scientists challenged to sequence genome and RNA content derived from single cancer cell

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

USPTO issues notice of allowance to Vermillion's breast cancer biomarkers

New study: Clinical trials exclude older patients due to age-related conditions

Researchers discover potential vaccine capable of reducing H. pylori colonization

Study: Simple sideline test can accurately detect concussions in athletes

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

Cutera launches Excel V laser system for Dermatologists and Plastic Surgeons

2010 Dietary Guidelines urge Americans to keep calorie intake from saturated fat to less than 10%

Study suggests human amniotic cells 'cross talk' with melatonin receptor MT1

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News